The global viral vector development market is expected to enjoy a valuation of US$ 730.7 Million by the end of the year 2023, and further expand at a CAGR of 18.7% to reach a valuation of US$ 4.1 Billion by the year 2033. According to the recent study by Future Market Insights, adeno-associated viral vectors (AAV) are leading the market with an expected share of about 37.0% in the year 2023, within the global market.
Market Outlook:
Data Points
Market Insights
Market Value 2022
US$ 624.7 Million
Market Value 2023
US$ 730.7 Million
Market Value 2033
US$ 4.1 Billion
CAGR 2023 to 2033
18.7%
Market Share of Top 5 Countries
57.5%
Key Market Players List
Thermo Fisher Scientific Inc, Charles River (Cobra Biologics), NOVASEP, uniQure N.V, Waisman Biomanufacturing, Creative Biogene, GenScript Biotech Corporation, Novartis AG , Merck KGaA, Takara Bio, Inc., FUJIFILM Diosynth Biotechnologies, LONZA, Danaher Corp. (Aldevron), Sirion Biotech GmbH, and AGC Biologics
Since viral vectors are created utilising animal cell cultures, and in some cases insect cell cultures, they are essentially made from viruses which naturally infect human or other mammalian cells. The last ten years have seen a tremendous advancement in manufacturing techniques for the development of clinical grade viral vectors. This is crucial for gene therapy methods implemented to the treatment of congenital or acquired disorders. AAV and lentiviral vectors are currently being used more frequently for in vivo and ex vivo gene delivery, respectively.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Sales Analysis of Viral Vector Development Market from 2017 to 2022 Vs Market Outlook for 2023 to 2033
The market value for viral vector development was approximately 35.5% of the overall ~US$ 30.86 Million of the global cancer gene therapy market in 2022.
The sale of viral vector development expanded at a CAGR of 14.5% from 2017 to 2022.
Traditional medicine researchers and the medical world have long believed that hereditary disorders are incurable. Genetic therapy, on the other hand, heralded a new era in medicine by offering the chance to fix the damaged genes that cause certain inherited illnesses.
Adeno-associated virus, often known as AAV, is frequently utilised as a carrier in the gene therapy procedure. The products made with viral vectors are proving to be suitable for the market because gene therapy has numerous potential applications in the medical sciences. Many biopharmaceutical companies are engaged in manufacturing and supply, which could be aimed at balancing the demand-supply ratio.
Despite the unexpected disruption of the world economy for all products during the pandemic years that followed the outbreak of COVID-19 infections, it offered tremendous chances for the viral vector CDMO business to expand globally. The search for a therapeutic approach and a vaccine to prevent the causal pathogen's rapid spread involved numerous research centres and private biopharmaceutical businesses.
It was necessary to cultivate a novel coronavirus in order to build any kind of countermeasure, which raised the need for viral vector products. Private manufacturing firms and public institutions developing viral vectors drove the production and supply of all varieties of viral vectors, including recombinant adenoviral vectors.
The AAV-based vaccine for COVID-19 infection prevention is currently been developed by a number of businesses and state organisations. The global viral vector market will be driven by the COVID-19, which is the subject of extensive research to produce a more effective vaccination for the upcoming years. Thus, owing to the aforementioned factors, the global viral vector development market is expected to grow at a CAGR of 18.7% during the forecast period between 2023 and 2033.
H1-H2 Update
Market Statistics
Details
Jan - Jun (H1), 2021 (A)
13.21%
Jul - Dec (H2), 2021 (A)
16.95%
Jan - Jun (H1),2022 Projected (P)
13.65%
Jan - Jun (H1),2022 Outlook (O)
14.28%
Jul - Dec (H2), 2022 Outlook (O)
17.66%
Jul - Dec (H2), 2022 Projected (P)
16.92%
Jan - Jun (H1), 2023 Projected (P)
15.08%
BPS Change : H1,2022 (O) - H1,2022 (P)
63↑
BPS Change : H1,2022 (O) - H1,2021 (A)
107↑
BPS Change: H2, 2022 (O) - H2, 2022 (P)
74↑
BPS Change: H2, 2022 (O) - H2, 2021 (A)
71↑
What are the Key Opportunities for the Market Players?
Gene therapy is necessary to repair suppressed and malfunctioning genes in human cells or tissues and return the abnormality to normal levels. Viral vector technology is used to cultivate the gene, and this business has grown significantly for many private players. For the most part, two different types of techniques are used to use viral vectors in the gene therapy-induced healing process.
When it comes to 2D planer technologies, scaling out of adherent cell systems is a common strategy that has been applied up until the point of market analysis. The production of suspension AAV by diverse segments will, therefore, rely increasingly on 3D suspension cell cultures or bioreactors in the upcoming period.
The synthesis of viral vectors using cell culture technology has been successfully modified to satisfy the demands of both early and advanced clinical trial phases. Scale-up, however, may still be constrained depending on the vector type and the cell culture production platforms chosen.
Presently, great progress is being made in the generation of cell lines that can create inducible or constitutively expressed lentiviral vectors that grow in suspension. Recently, the first batch of lentiviral vectors generated by reliable producer cell lines was utilised in a clinical trial setting.
With extensive safety and efficacy data gathered from various clinical trials, it is evident that gene therapy is making great progress. These factors are set to promote the expansion of the global market, over the forecast period.
Find your sweet spots for generating winning opportunities in this market.
What are the Factors Restraining Demand for Viral Vector Development?
The deployment of exceedingly complex procedures was brought about by the need for clinical-grade, thoroughly polished final products. For the initial set of production units, such advanced technological techniques require a significant investment from the viral vector firms.
The primary barrier to the rapid development of viral vectors for varied purposes remains the strict government requirements for sanctioning any new development related to the healthcare sector.
The global viral vector development market's expansion is undoubtedly constrained by the lack of enough good laboratories for the testing and approval of essential raw materials.
Due to its superior safety profile and effective transduction to a variety of target tissues, adeno-associated virus (AAV) has become a major platform for the delivery of genes for the treatment of many disorders. Viral vectors are less effective than recombinant protein treatments in large-scale production and long-term preservation, which results in lower yields, a modest level of purity, and a shorter shelf life.
The cost-effective manufacture of viral vectors remains a challenge despite notable clinical and commercial accomplishments, primarily because it is unclear how different methods affect the quality and shelf-life of AAV products.
This is because AAV gene therapy's clinical progress has outpaced its CMC, manufacturing, and formulation development. These factors are expected to restrain the market expansion over the forecast period.
Country-wise Insights
Country
The USA
Market Share (2023)
33.5%
Market Share (2033)
31.8%
BPS Analysis
-169
Country
China
Market Share (2023)
6.7%
Market Share (2033)
4.2%
BPS Analysis
-245
Country
UK
Market Share (2023)
6.4%
Market Share (2033)
7.1%
BPS Analysis
63
Country
Germany
Market Share (2023)
5.8%
Market Share (2033)
7.6%
BPS Analysis
177
Country
Japan
Market Share (2023)
4.8%
Market Share (2033)
2.7%
BPS Analysis
-208
What Makes the USA a Large Market for Viral Vector Development?
The USA dominates the globe with a total market share of about 33.1% in 2022, and is expected to continue to experience the same growth throughout the forecast period.
One of the key reasons fueling the market's growth throughout the forecast period is the rising number of patients choosing gene therapy to treat diseases like hemophilia, heart disease, diabetes, cystic fibrosis, cancer, and AIDS. The increased development of gene therapy has increased the demand for plasmid DNA. Collaborations between businesses, various organizations, academic institutions, and nonprofit groups are growing as they work to create viral vectors and plasmid DNA. These elements encourage market expansion in the United States.
What is the Outlook of Germany in the Viral Vector Development Market?
Germany held a market share of nearly 5.6% in the global viral vector development market in 2022.
In February 2020, the US production facility of the German-based viral vector company Vibalogics, CDMO was established. By providing CDMO viral vector, this facility in Massachusetts that was developed with a $150 million investment, is anticipated to seize the North American market. With such expansions taking place among the key players into developing regions, the market is set to expand in Germany
How is the Market Expected to Grow in China?
China held a share of around 7.1% in the global market, in 2022.
In order to increase its capabilities and production capacity, VectorBuilder stated in April 2022 that it would build a $500 million gene delivery and research facility in Guangzhou, China.
The "Gene Delivery Research and Manufacturing Campus," as it has been dubbed by contract development manufacturing organization (CDMO) VectorBuilder, which offers gene delivery systems, will be constructed over the course of four years.
The campus will have 30 production suites, according to the company, that can produce plasmids, cell lines, adeno-associated virus (AAV), lentivirus, messenger RNA (mRNA), and other viral and non-viral vectors.
Such advancements within the country are expected to propel the growth of the overall market throughout the forecast period.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Category-wise Insights
Which Virus is Largely Adopted for Viral Vector Development?
Adeno-associated viral vectors are set to hold a share of around 37.0% in the global market, in 2023.
Adeno-associated viral vectors are the most efficient way to transfer genes to treat a wide range of human illnesses. Recent advancements in the design of therapeutically appealing AAV capsids, genome optimization, and the use of advanced biotechnologies have resulted in a considerable expansion of the area of gene therapy. Two AAV-based drugs have been approved by regulators in the US or Europe, proving the clinical and preclinical efficacy of AAV as the ideal therapeutic vector for gene editing, gene silencing, and gene substitution.
What Expression Systems are Primarily in Focus Globally?
The stable expression system will hold a global market share of around 85.80% in 2023.
Owing of its intricacy, viral vector manufacturing is still evolving. The majority of researchers acknowledge that obtaining sufficient yields of functional capsids with the required genetic payload represents the biggest challenge. The most commonly used strategy is transient transfection, which effectively creates a cell line for every production cycle or a "cell factory" for a single production cycle. A stable and optimised manufacturing cell line, analogous to the ones used for other biologics, would provide a more reliable approach and be scalable if cells were cultured in suspension. Over the anticipated years, this is expected to increase the segment value.
Which Application of Viral Vector Development is Largely Profitable within the Global Market?
Gene therapy applications are set to hold a market share of around 55.1% in the global market in 2023.
Because viruses have proven to be particularly effective at entering cells, vectors are frequently created from them. All viral genes are removed from vectors before they are changed to solely carry therapeutic genes, making them safe to employ. Three different types of vectors—adeno-associated virus (AAV) vectors, adenovirus vectors, or lentivirus vectors—are used by almost all gene therapies currently on the market.
Viral vectors are used in gene therapy to address more than just symptoms. With the genetic information they contain, vectors can modify a cell's behavior and target the underlying cause of a disease. They are frequently used for uncommon genetic disorders for whom there are few to no other effective treatments, and they normally only need to be delivered once.
How are Academic and Research Institutes Contributing towards Market Growth?
Academic and Research Institutes are set to hold a significant market share of around 45.7% globally, in 2023.
According to data provided by the WHO and FDA, by February 2022, there were 114 candidate vaccines in clinical trials, 75 animal preclinical trials, and 14 vaccinations that have been licensed for emergency use. In order to develop drug candidates more efficiently, with enhanced therapeutic potential and greater access for patients worldwide, there has been a surge in collaborations between pharmaceutical companies and academic and research institutes, thus propelling segment growth within the overall market.
Comparative View of the Adjacent Viral Vector Development Market
Viral Vector Development Market:
Attributes
Viral Vector Development Market
CAGR (2023 to 2033)
18.7%
Market Value (2023)
US$ 730.7 Million
Growth Factor
Growing developments in gene therapy safety, immune response control, and cost reduction in manufacturing are the key market drivers. Regulators have used reducing the empty-to-full capsid ratio as justification for removing clinical holds on gene-therapy products that had previously encountered safety problems.
Key Market Trend
Focus on development of novel gene therapies.
Cancer Gene Therapy Market:
Attributes
Cancer Gene Therapy Market
CAGR (2023 to 2033)
10.1%
Market Value (2023)
US$ 2.2 Billion
Growth Factor
Developments in oncolytic viral therapy and advancements in technology are the key drivers of the market. Rising investments in cancer research and increasing demand for novel biologics are further propelling factors adding towards market expansion.
Key Trend
Governments are expanding awareness programs for cancer research. There is also an increasing ethical acceptability of gene therapy owed to favorable results obtained through clinical trials.
Oncology Blood Testing Market:
Attributes
Oncology Blood Testing Market
CAGR (2023 to 2033)
15.2%
Market Value (2023)
US$ 4.44 Billion
Growth Factor
Companies offer a variety of molecular decision support systems that combine genomic and clinical data to fill gaps in precision medicine practice, increasing demand for oncology blood tests.
Key Trend
The significant market trends are increasing cases of hematologic or blood cancer, increasing demand for oncology blood tests due to advantageous and straightforward reimbursement policies, and increasing awareness of advanced treatment options.
Competitive Landscape
The market for the production of plasmid DNA and viral vector CDMO has become extremely competitive in recent years as a result of the introduction of numerous companies in these industries. The main tactic used by the leading firms to stay ahead of their rivals is the expansion of production facilities. A cost-effective strategy for the rapid expansion and capacity building for viral vector process development for the manufacturers is the acquisition of small regional companies.
Recent Market Developments
In February 2020, German-based viral vector company CDMO expanded its facility in Massachusetts, United States. The company raised a funding of US$ 150 Million for providing CDMO viral vectors in North America.
In January 2021, Thermo Fisher Scientific acquired Viral vector manufacturing firm, Groupe Novasep SAS. The acquisition is expected to expand ThermoFisher’s service portfolio catering to scientific viral vector in North American market.
Similarly, recent developments have been tracked by the team at Future Market Insights related to companies in the viral vector development market, which are available in the full report.
Report Scope as per Viral Vector Development Industry Analysis
Attribute
Details
Forecast Period
2023 to 2033
Historical Data Available for
2017 to 2022
Market Analysis
US$ Million for Value
Key Regions Covered
North America, Latin America, Europe, South Asia, East Asia, Oceania, and Middle East & Africa
Key Countries Covered
USA, Canada, Brazil, Mexico, Argentina, UK, Germany, Italy, Russia, Spain, France, BENELUX, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Türkiye, GCC Countries, North Africa, and South Africa
Key Market Segments Covered
Virus, Application, Expression System, End User, and Region
Key Market Segments Covered in Viral Vector Development Industry Research
Virus:
Lentiviral Vectors
Adenoviral Vectors
Adeno-Associated Viral Vectors
Retrovirus
Expression System:
Transient
Stable
Application:
Gene Therapy
Vaccines
Cancer Therapy
Others
End User:
Biotechnology Companies
Pharmaceutical Companies
Contract Research Organization (CRO)
Academic and Research Institutes
Region:
North America
Latin America
Europe
South Asia
East Asia
Oceania
The Middle East and Africa (MEA)
Frequently Asked Questions
The viral vector development market is pegged at a value of US$ 730.7 million in 2023.
The viral vector development market is estimated to reach US$ 4.1 billion by 2033.
Sales of viral vector development are anticipated to surge at a noteworthy CAGR of 18.7% through 2033.
The United States has turned into a key hub in the market with a sizeable share of 33.1% in 2022.
The viral vector development market reached a value of US$ 624.7 million In 2022.
Table of Content
1. Executive Summary | Viral Vector Development Market
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Market Innovation / Development Trends
4. Key Success Factors
4.1. Disease Epidemiology, by Region
4.2. Technological Assessment
4.3. Regulatory Landscape
4.4. Promotional Strategies, By Key Players
4.5. PESTEL Analysis
4.6. Porter’s Analysis
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Growth Outlook
5.1.2. Global Healthcare Outlook
5.1.3. Global Cancer Gene Therapy Market Overview
5.2. Forecast Factors - Relevance & Impact
5.2.1. Rising Prevalence of Chronic Diseases
5.2.2. Increasing Research and Development in Oncology Gene Therapy
5.2.3. Rising Investments in Viral Gene Therapy
5.2.4. New Product Launch Activities
5.2.5. Technological Advancements
5.2.6. Regulatory Impositions
5.2.7. Growing CMO/CDMO Activities
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. COVID-19 Crisis Analysis
6.1. COVID-19 and Impact Analysis
6.1.1. By Virus
6.1.2. By Expression System
6.1.3. By Application
6.1.4. By End User
6.1.5. By Country
6.2. 2022 Market Scenario
7. Global Market Demand (in Value or Size in US$ Million) Analysis 2017 to 2022 and Forecast, 2023 to 2033
7.1. Historical Market Value (US$ Million) Analysis, 2017 to 2022
7.2. Current and Future Market Size (US$ Million) Analysis and Forecast, 2023 to 2033
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Virus
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Million) Analysis By Virus, 2017 to 2022
8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Virus, 2023 to 2033
8.3.1. Lentiviral Vectors
8.3.2. Adenoviral Vectors
8.3.3. Adeno-Associated Viral Vectors
8.3.4. Retrovirus
8.4. Market Attractiveness Analysis By Virus
9. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Expression System
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Million) Analysis, By Expression System, 2017 to 2022
9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Expression System, 2023 to 2033
9.3.1. Transient
9.3.2. Stable
9.4. Market Attractiveness Analysis By Expression System
10. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Application
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Million) Analysis By Application, 2017 to 2022
10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Application, 2023 to 2033
10.3.1. Gene Therapy
10.3.2. Vaccines
10.3.3. Cancer Therapy
10.3.4. Others
10.4. Market Attractiveness Analysis By Application
11. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By End User
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Million) Analysis, By End User, 2017 to 2022
11.3. Current and Future Market Size (US$ Million) Analysis Forecast By End User, 2023 to 2033
11.3.1. Biotechnology Companies
11.3.2. Pharmaceutical Companies
11.3.3. Contract Research Organization (CRO)
11.3.4. Academic and Research Institutes
11.4. Market Attractiveness Analysis By End User
12. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Region
12.1. Introduction
12.2. Historical Market Size (US$ Million) Analysis By Region, 2017 to 2022
12.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Region, 2023 to 2033
12.3.1. North America
12.3.2. Latin America
12.3.3. Europe
12.3.4. East Asia
12.3.5. South Asia
12.3.6. Oceania
12.3.7. Middle East and Africa (MEA)
12.4. Market Attractiveness Analysis By Region
13. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033
13.1. Introduction
13.2. Historical Market Size (US$ Million) Analysis Trend Analysis By Market Taxonomy, 2017 to 2022
13.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
13.3.1. By Country
13.3.1.1. USA
13.3.1.2. Canada
13.3.2. By Virus
13.3.3. By Expression System
13.3.4. By Application
13.3.5. By End User
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Virus
13.4.3. By Expression System
13.4.4. By Application
13.4.5. By End User
13.5. Market Trends
13.6. Key Market Participants - Intensity Mapping
13.7. Drivers and Restraints - Impact Analysis
13.8. Country Level Analysis & Forecast
13.8.1. USA Market Analysis
13.8.1.1. .Introduction
13.8.1.2. Market Analysis and Forecast by Market Taxonomy
13.8.1.2.1. By Virus
13.8.1.2.2. By Expression System
13.8.1.2.3. By Application
13.8.1.2.4. By End User
13.8.2. Canada Market Analysis
13.8.2.1. Introduction
13.8.2.2. Market Analysis and Forecast by Market Taxonomy
13.8.2.2.1. By Virus
13.8.2.2.2. By Expression System
13.8.2.2.3. By Application
13.8.2.2.4. By End User
14. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033
14.1. Introduction
14.2. Historical Market Size (US$ Million) Analysis Trend Analysis By Market Taxonomy, 2017 to 2022
14.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
14.3.1. By Country
14.3.1.1. Mexico
14.3.1.2. Brazil
14.3.1.3. Argentina
14.3.1.4. Rest of Latin America
14.3.2. By Virus
14.3.3. By Expression System
14.3.4. By Application
14.3.5. By End User
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Virus
14.4.3. By Expression System
14.4.4. By Application
14.4.5. By End User
14.5. Market Trends
14.6. Key Market Participants - Intensity Mapping
14.7. Drivers and Restraints - Impact Analysis
14.8. Country Level Analysis & Forecast
14.8.1. Mexico Market Analysis
14.8.1.1. Introduction
14.8.1.2. Market Analysis and Forecast by Market Taxonomy
14.8.1.2.1. By Virus
14.8.1.2.2. By Expression System
14.8.1.2.3. By Application
14.8.1.2.4. By End User
14.8.2. Brazil Market Analysis
14.8.2.1. Introduction
14.8.2.2. Market Analysis and Forecast by Market Taxonomy
14.8.2.2.1. By Virus
14.8.2.2.2. By Expression System
14.8.2.2.3. By Application
14.8.2.2.4. By End User
14.8.3. Argentina Market Analysis
14.8.3.1. Introduction
14.8.3.2. Market Analysis and Forecast by Market Taxonomy
14.8.3.2.1. By Virus
14.8.3.2.2. By Expression System
14.8.3.2.3. By Application
14.8.3.2.4. By End User
15. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033
15.1. Introduction
15.2. Historical Market Size (US$ Million) Analysis Trend Analysis By Market Taxonomy, 2017 to 2022
15.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
15.3.1. By Country
15.3.1.1. Germany
15.3.1.2. Italy
15.3.1.3. France
15.3.1.4. United Kingdom
15.3.1.5. Spain
15.3.1.6. BENELUX
15.3.1.7. Russia
15.3.1.8. Rest of Europe
15.3.2. By Virus
15.3.3. By Expression System
15.3.4. By Application
15.3.5. By End User
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Virus
15.4.3. By Expression System
15.4.4. By Application
15.4.5. By End User
15.5. Market Trends
15.6. Key Market Participants - Intensity Mapping
15.7. Drivers and Restraints - Impact Analysis
15.8. Country Level Analysis & Forecast
15.8.1. Germany Market Analysis
15.8.1.1. Introduction
15.8.1.2. Market Analysis and Forecast by Market Taxonomy
15.8.1.2.1. By Virus
15.8.1.2.2. By Expression System
15.8.1.2.3. By Application
15.8.1.2.4. By End User
15.8.2. Italy Market Analysis
15.8.2.1. Introduction
15.8.2.2. Market Analysis and Forecast by Market Taxonomy
15.8.2.2.1. B By Virus
15.8.2.2.2. By Expression System
15.8.2.2.3. By Application
15.8.2.2.4. By End User
15.8.3. France Market Analysis
15.8.3.1. Introduction
15.8.3.2. Market Analysis and Forecast by Market Taxonomy
15.8.3.2.1. By Virus
15.8.3.2.2. By Expression System
15.8.3.2.3. By Application
15.8.3.2.4. By End User
15.8.4. United Kingdom Market Analysis
15.8.4.1. Introduction
15.8.4.2. Market Analysis and Forecast by Market Taxonomy
15.8.4.2.1. By Virus
15.8.4.2.2. By Expression System
15.8.4.2.3. By Application
15.8.4.2.4. By End User
15.8.5. Spain Market Analysis
15.8.5.1. Introduction
15.8.5.2. Market Analysis and Forecast by Market Taxonomy
15.8.5.2.1. By Virus
15.8.5.2.2. By Expression System
15.8.5.2.3. By Application
15.8.5.2.4. By End User
15.8.6. BENELUX Market Analysis
15.8.6.1. Introduction
15.8.6.2. Market Analysis and Forecast by Market Taxonomy
15.8.6.2.1. By Virus
15.8.6.2.2. By Expression System
15.8.6.2.3. By Application
15.8.6.2.4. By End User
15.8.7. Russia Market Analysis
15.8.7.1. Introduction
15.8.7.2. Market Analysis and Forecast by Market Taxonomy
15.8.7.2.1. By Virus
15.8.7.2.2. By Expression System
15.8.7.2.3. By Application
15.8.7.2.4. By End User
16. East Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033
16.1. Introduction
16.2. Historical Market Size (US$ Million) Analysis Trend Analysis By Market Taxonomy, 2017 to 2022
16.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
16.3.1. By Country
16.3.1.1. China
16.3.1.2. Japan
16.3.1.3. South Korea
16.3.2. By Virus
16.3.3. By Expression System
16.3.4. By Application
16.3.5. By End User
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Virus
16.4.3. By Expression System
16.4.4. By Application
16.4.5. By End User
16.5. Market Trends
16.6. Key Market Participants - Intensity Mapping
16.7. Drivers and Restraints - Impact Analysis
16.8. Country Level Analysis & Forecast
16.8.1. China Market Analysis
16.8.1.1. Introduction
16.8.1.2. Market Analysis and Forecast by Market Taxonomy
16.8.1.2.1. By Virus
16.8.1.2.2. By Expression System
16.8.1.2.3. By Application
16.8.1.2.4. By End User
16.8.2. Japan Market Analysis
16.8.2.1. Introduction
16.8.2.2. Market Analysis and Forecast by Market Taxonomy
16.8.2.2.1. By Virus
16.8.2.2.2. By Expression System
16.8.2.2.3. By Application
16.8.2.2.4. By End User
16.8.3. South Korea Market Analysis
16.8.3.1. Introduction
16.8.3.2. Market Analysis and Forecast by Market Taxonomy
16.8.3.2.1. By Virus
16.8.3.2.2. By Expression System
16.8.3.2.3. By Application
16.8.3.2.4. By End User
17. South Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033
17.1. Introduction
17.2. Historical Market Size (US$ Million) Analysis Trend Analysis By Market Taxonomy, 2017 to 2022
17.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
17.3.1. By Country
17.3.1.1. India
17.3.1.2. Indonesia
17.3.1.3. Malaysia
17.3.1.4. Thailand
17.3.1.5. Rest of South Asia
17.3.2. By Virus
17.3.3. By Expression System
17.3.4. By Application
17.3.5. By End User
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Virus
17.4.3. By Expression System
17.4.4. By Application
17.4.5. By End User
17.5. Market Trends
17.6. Key Market Participants - Intensity Mapping
17.7. Drivers and Restraints - Impact Analysis
17.8. Country Level Analysis & Forecast
17.8.1. India Market Analysis
17.8.1.1. Introduction
17.8.1.2. Market Analysis and Forecast by Market Taxonomy
17.8.1.2.1. By Virus
17.8.1.2.2. By Expression System
17.8.1.2.3. By Application
17.8.1.2.4. By End User
17.8.2. Indonesia Market Analysis
17.8.2.1. Introduction
17.8.2.2. Market Analysis and Forecast by Market Taxonomy
17.8.2.2.1. By Virus
17.8.2.2.2. By Expression System
17.8.2.2.3. By Application
17.8.2.2.4. By End User
17.8.3. Malaysia Market Analysis
17.8.3.1. Introduction
17.8.3.2. Market Analysis and Forecast by Market Taxonomy
17.8.3.2.1. By Virus
17.8.3.2.2. By Expression System
17.8.3.2.3. By Application
17.8.3.2.4. By End User
17.8.4. Thailand Market Analysis
17.8.4.1. Introduction
17.8.4.2. Market Analysis and Forecast by Market Taxonomy
17.8.4.2.1. By Virus
17.8.4.2.2. By Expression System
17.8.4.2.3. By Application
17.8.4.2.4. By End User
18. Oceania Market 2017 to 2022 and Forecast 2023 to 2033
18.1. Introduction
18.2. Historical Market Size (US$ Million) Analysis Trend Analysis By Market Taxonomy, 2017 to 2022
18.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
18.3.1. By Country
18.3.1.1. Australia
18.3.1.2. New Zealand
18.3.2. By Virus
18.3.3. By Expression System
18.3.4. By Application
18.3.5. By End User
18.4. Market Attractiveness Analysis
18.4.1. By Country
18.4.2. By Virus
18.4.3. By Expression System
18.4.4. By Application
18.4.5. By End User
18.5. Market Trends
18.6. Key Market Participants - Intensity Mapping
18.7. Drivers and Restraints - Impact Analysis
18.8. Country Level Analysis & Forecast
18.8.1. Australia Market Analysis
18.8.1.1. Introduction
18.8.1.2. Market Analysis and Forecast by Market Taxonomy
18.8.1.2.1. By Virus
18.8.1.2.2. By Expression System
18.8.1.2.3. By Application
18.8.1.2.4. By End User
18.8.2. New Zealand Market Analysis
18.8.2.1. Introduction
18.8.2.2. Market Analysis and Forecast by Market Taxonomy
18.8.2.2.1. By Virus
18.8.2.2.2. By Expression System
18.8.2.2.3. By Application
18.8.2.2.4. By End User
19. Middle East and Africa (MEA) Market Analysis 2017 to 2022 and Forecast 2023 to 2033
19.1. Introduction
19.2. Historical Market Size (US$ Million) Analysis Trend Analysis By Market Taxonomy, 2017 to 2022
19.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
19.3.1. By Country
19.3.1.1. GCC Countries
19.3.1.2. Türkiye
19.3.1.3. North Africa
19.3.1.4. South Africa
19.3.1.5. Rest of Middle East and Africa
19.3.2. By Virus
19.3.3. By Expression System
19.3.4. By Application
19.3.5. By End User
19.4. Market Attractiveness Analysis
19.4.1. By Country
19.4.2. By Virus
19.4.3. By Expression System
19.4.4. By Application
19.4.5. By End User
19.5. Market Trends
19.6. Key Market Participants - Intensity Mapping
19.7. Drivers and Restraints - Impact Analysis
19.8. Country Level Analysis & Forecast
19.8.1. GCC Countries Market Analysis
19.8.1.1. Introduction
19.8.1.2. Market Analysis and Forecast by Market Taxonomy
19.8.1.2.1. By Virus
19.8.1.2.2. By Expression System
19.8.1.2.3. By Application
19.8.1.2.4. By End User
19.8.2. Türkiye Market Analysis
19.8.2.1. Introduction
19.8.2.2. Market Analysis and Forecast by Market Taxonomy
19.8.2.2.1. By Virus
19.8.2.2.2. By Expression System
19.8.2.2.3. By Application
19.8.2.2.4. By End User
19.8.3. South Africa Market Analysis
19.8.3.1. Introduction
19.8.3.2. Market Analysis and Forecast by Market Taxonomy
19.8.3.2.1. By Virus
19.8.3.2.2. By Expression System
19.8.3.2.3. By Application
19.8.3.2.4. By End User
19.8.4. North Africa Market Analysis
19.8.4.1. Introduction
19.8.4.2. Market Analysis and Forecast by Market Taxonomy
19.8.4.2.1. By Virus
19.8.4.2.2. By Expression System
19.8.4.2.3. By Application
19.8.4.2.4. By End User
20. Market Structure Analysis
20.1. Market Analysis by Tier of Companies
20.2. Market Share Analysis of Top Players
20.3. Market Presence Analysis
21. Competition Analysis
21.1. Competition Dashboard
21.2. Competition Benchmarking
21.3. Competition Deep Dive
21.3.1. Thermo Fisher Scientific Inc
21.3.1.1. Overview
21.3.1.2. Product Overview
21.3.1.3. Sales Footprint
21.3.1.4. Key Financials
21.3.1.5. SWOT Analysis
21.3.1.6. Strategy Overview
21.3.1.6.1. Marketing Strategy
21.3.1.6.2. Product Strategy
21.3.1.6.3. Channel Strategy
21.3.2. Charles River (Cobra Biologics)
21.3.2.1. Overview
21.3.2.2. Product Overview
21.3.2.3. Sales Footprint
21.3.2.4. Key Financials
21.3.2.5. SWOT Analysis
21.3.2.6. Strategy Overview
21.3.2.6.1. Marketing Strategy
21.3.2.6.2. Product Strategy
21.3.2.6.3. Channel Strategy
21.3.3. NOVASEP
21.3.3.1. Overview
21.3.3.2. Product Overview
21.3.3.3. Sales Footprint
21.3.3.4. Key Financials
21.3.3.5. SWOT Analysis
21.3.3.6. Strategy Overview
21.3.3.6.1. Marketing Strategy
21.3.3.6.2. Product Strategy
21.3.3.6.3. Channel Strategy
21.3.4. uniQure N.V
21.3.4.1. Overview
21.3.4.2. Product Overview
21.3.4.3. Sales Footprint
21.3.4.4. Key Financials
21.3.4.5. SWOT Analysis
21.3.4.6. Strategy Overview
21.3.4.6.1. Marketing Strategy
21.3.4.6.2. Product Strategy
21.3.4.6.3. Channel Strategy
21.3.5. Waisman Biomanufacturing
21.3.5.1. Overview
21.3.5.2. Product Overview
21.3.5.3. Sales Footprint
21.3.5.4. Key Financials
21.3.5.5. SWOT Analysis
21.3.5.6. Strategy Overview
21.3.5.6.1. Marketing Strategy
21.3.5.6.2. Product Strategy
21.3.5.6.3. Channel Strategy
21.3.6. Creative Biogene
21.3.6.1. Overview
21.3.6.2. Product Overview
21.3.6.3. Sales Footprint
21.3.6.4. Key Financials
21.3.6.5. SWOT Analysis
21.3.6.6. Strategy Overview
21.3.6.6.1. Marketing Strategy
21.3.6.6.2. Product Strategy
21.3.6.6.3. Channel Strategy
21.3.7. GenScript Biotech Corporation
21.3.7.1. Overview
21.3.7.2. Product Overview
21.3.7.3. Sales Footprint
21.3.7.4. Key Financials
21.3.7.5. SWOT Analysis
21.3.7.6. Strategy Overview
21.3.7.6.1. Marketing Strategy
21.3.7.6.2. Product Strategy
21.3.7.6.3. Channel Strategy
21.3.8. Novartis AG
21.3.8.1. Overview
21.3.8.2. Product Overview
21.3.8.3. Sales Footprint
21.3.8.4. Key Financials
21.3.8.5. SWOT Analysis
21.3.8.6. Strategy Overview
21.3.8.6.1. Marketing Strategy
21.3.8.6.2. Product Strategy
21.3.8.6.3. Channel Strategy
21.3.9. Merck KGaA
21.3.9.1. Overview
21.3.9.2. Product Overview
21.3.9.3. Sales Footprint
21.3.9.4. Key Financials
21.3.9.5. SWOT Analysis
21.3.9.6. Strategy Overview
21.3.9.6.1. Marketing Strategy
21.3.9.6.2. Product Strategy
21.3.9.6.3. Channel Strategy
21.3.10. Takara Bio, Inc.
21.3.10.1. Overview
21.3.10.2. Product Overview
21.3.10.3. Sales Footprint
21.3.10.4. Key Financials
21.3.10.5. SWOT Analysis
21.3.10.6. Strategy Overview
21.3.10.6.1. Marketing Strategy
21.3.10.6.2. Product Strategy
21.3.10.6.3. Channel Strategy
21.3.11. FUJIFILM Diosynth Biotechnologies
21.3.11.1. Overview
21.3.11.2. Product Overview
21.3.11.3. Sales Footprint
21.3.11.4. Key Financials
21.3.11.5. SWOT Analysis
21.3.11.6. Strategy Overview
21.3.11.6.1. Marketing Strategy
21.3.11.6.2. Product Strategy
21.3.11.6.3. Channel Strategy
21.3.12. LONZA
21.3.12.1. Overview
21.3.12.2. Product Overview
21.3.12.3. Sales Footprint
21.3.12.4. Key Financials
21.3.12.5. SWOT Analysis
21.3.12.6. Strategy Overview
21.3.12.6.1. Marketing Strategy
21.3.12.6.2. Product Strategy
21.3.12.6.3. Channel Strategy
21.3.13. Danaher Corp. (Aldevron)
21.3.13.1. Overview
21.3.13.2. Product Overview
21.3.13.3. Sales Footprint
21.3.13.4. Key Financials
21.3.13.5. SWOT Analysis
21.3.13.6. Strategy Overview
21.3.13.6.1. Marketing Strategy
21.3.13.6.2. Product Strategy
21.3.13.6.3. Channel Strategy
21.3.14. Sirion Biotech GmbH
21.3.14.1. Overview
21.3.14.2. Product Overview
21.3.14.3. Sales Footprint
21.3.14.4. Key Financials
21.3.14.5. SWOT Analysis
21.3.14.6. Strategy Overview
21.3.14.6.1. Marketing Strategy
21.3.14.6.2. Product Strategy
21.3.14.6.3. Channel Strategy
21.3.15. AGC Biologics
21.3.15.1. Overview
21.3.15.2. Product Overview
21.3.15.3. Sales Footprint
21.3.15.4. Key Financials
21.3.15.5. SWOT Analysis
21.3.15.6. Strategy Overview
21.3.15.6.1. Marketing Strategy
21.3.15.6.2. Product Strategy
21.3.15.6.3. Channel Strategy
22. Assumptions and Acronyms Used23. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 01: Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Virus
Table 02: Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Expression System
Table 03: Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Application
Table 04: Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by End User
Table 05: Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Region
Table 06: North America Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Country
Table 07: North America Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Virus
Table 08: North America Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Expression System
Table 09: North America Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Application
Table 10: North America Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by End User
Table 11: Latin America Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Country
Table 12: Latin America Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Virus
Table 13: Latin America Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Expression System
Table 14: Latin America Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Application
Table 15: Latin America Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by End User
Table 16: Europe Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Country
Table 17: Europe Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Virus
Table 18: Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Expression System
Table 19: Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Application
Table 20: Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by End User
Table 21: East Asia Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Country
Table 22: East Asia Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Virus
Table 23: East Asia Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Expression System
Table 24: East Asia Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Application
Table 25: East Asia Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by End User
Table 26: South Asia Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Country
Table 27: South Asia Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Virus
Table 28: South Asia Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Expression System
Table 29: South Asia Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Application
Table 30: South Asia Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by End User
Table 31: Oceania Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Country
Table 32: Oceania Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Virus
Table 33: Oceania Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Expression System
Table 34: Oceania Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Application
Table 35: Oceania Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by End User
Table 36: Middle East & Africa Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Country
Table 37: Middle East & Africa Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Virus
Table 38: Middle East & Africa Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Expression System
Table 39: Middle East & Africa Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Application
Table 40: Middle East & Africa Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by End User
Find your sweet spots for generating winning opportunities in this market.
List of Charts
Figure 01: Global Market Value (US$ Million) Analysis, 2017 to 2022
Figure 02: Global Market Forecast & Y-o-Y Growth, 2023 to 2033
Figure 03: Global Market Absolute $ Opportunity (US$ Million) Analysis, 2022 to 2033
Figure 04: Global Market Value Share (%) Analysis 2023 and 2033, by Virus
Figure 05: Global Market Y-o-Y Growth (%) Analysis 2022-2033, by Virus
Figure 06: Global Market Attractiveness Analysis 2023 to 2033, by Virus
Figure 07: Global Market Value Share (%) Analysis 2023 and 2033, by Expression System
Figure 08: Global Market Y-o-Y Growth (%) Analysis 2022-2033, by Expression System
Figure 09: Global Market Attractiveness Analysis 2023 to 2033, by Expression System
Figure 10: Global Market Value Share (%) Analysis 2023 and 2033, by Application
Figure 11: Global Market Y-o-Y Growth (%) Analysis 2022-2033, by Application
Figure 12: Global Market Attractiveness Analysis 2023 to 2033, by Application
Figure 13: Global Market Value Share (%) Analysis 2023 and 2033, by End User
Figure 14: Global Market Y-o-Y Growth (%) Analysis 2022-2033, by End User
Figure 15: Global Market Attractiveness Analysis 2023 to 2033, by End User
Figure 16: Global Market Value Share (%) Analysis 2023 and 2033, by Region
Figure 17: Global Market Y-o-Y Growth (%) Analysis 2022-2033, by Region
Figure 18: Global Market Attractiveness Analysis 2023 to 2033, by Region
Figure 19: North America Market Value (US$ Million) Analysis, 2017 to 2022
Figure 20: North America Market Value (US$ Million) Forecast, 2023-2033
Figure 21: North America Market Value Share, by Virus (2023 E)
Figure 22: North America Market Value Share, by Expression System (2023 E)
Figure 23: North America Market Value Share, by Application (2023 E)
Figure 24: North America Market Value Share, by End User (2023 E)
Figure 25: North America Market Value Share, by Country (2023 E)
Figure 26: North America Market Attractiveness Analysis by Virus, 2023 to 2033
Figure 27: North America Market Attractiveness Analysis by Expression System, 2023 to 2033
Figure 28: North America Market Attractiveness Analysis by Application, 2023 to 2033
Figure 29: North America Market Attractiveness Analysis by End User, 2023 to 2033
Figure 30: North America Market Attractiveness Analysis by Country, 2023 to 2033
Figure 31: USA Market Value Proportion Analysis, 2022
Figure 32: Global Vs. USA Growth Comparison
Figure 33: USA Market Share Analysis (%) by Virus, 2022 to 2033
Figure 34: USA Market Share Analysis (%) by Expression System, 2022 to 2033
Figure 35: USA Market Share Analysis (%) by Application, 2022 to 2033
Figure 36: USA Market Share Analysis (%) by End User, 2022 to 2033
Figure 37: Canada Market Value Proportion Analysis, 2022
Figure 38: Global Vs. Canada. Growth Comparison
Figure 39: Canada Market Share Analysis (%) by Virus, 2022 to 2033
Figure 40: Canada Market Share Analysis (%) by Expression System, 2022 to 2033
Figure 41: Canada Market Share Analysis (%) by Application, 2022 to 2033
Figure 42: Canada Market Share Analysis (%) by End User, 2022 to 2033
Figure 43: Latin America Market Value (US$ Million) Analysis, 2017 to 2022
Figure 44: Latin America Market Value (US$ Million) Forecast, 2023-2033
Figure 45: Latin America Market Value Share, by Virus (2023 E)
Figure 46: Latin America Market Value Share, by Expression System (2023 E)
Figure 47: Latin America Market Value Share, by Application (2023 E)
Figure 48: Latin America Market Value Share, by End User (2023 E)
Figure 49: Latin America Market Value Share, by Country (2023 E)
Figure 50: Latin America Market Attractiveness Analysis by Virus, 2023 to 2033
Figure 51: Latin America Market Attractiveness Analysis by Expression System, 2023 to 2033
Figure 52: Latin America Market Attractiveness Analysis by Application, 2023 to 2033
Figure 53: Latin America Market Attractiveness Analysis by End User, 2023 to 2033
Figure 54: Latin America Market Attractiveness Analysis by Country, 2023 to 2033
Figure 55: Mexico Market Value Proportion Analysis, 2022
Figure 56: Global Vs Mexico Growth Comparison
Figure 57: Mexico Market Share Analysis (%) by Virus, 2022 to 2033
Figure 58: Mexico Market Share Analysis (%) by Expression System, 2022 to 2033
Figure 59: Mexico Market Share Analysis (%) by Application, 2022 to 2033
Figure 60: Mexico Market Share Analysis (%) by End User, 2022 to 2033
Figure 61: Brazil Market Value Proportion Analysis, 2022
Figure 62: Global Vs. Brazil. Growth Comparison
Figure 63: Brazil Market Share Analysis (%) by Virus, 2022 to 2033
Figure 64: Brazil Market Share Analysis (%) by Expression System, 2022 to 2033
Figure 65: Brazil Market Share Analysis (%) by Application, 2022 to 2033
Figure 66: Brazil Market Share Analysis (%) by End User, 2022 to 2033
Figure 67: Argentina Market Value Proportion Analysis, 2022
Figure 68: Global Vs Argentina Growth Comparison
Figure 69: Argentina Market Share Analysis (%) by Virus, 2022 to 2033
Figure 70: Argentina Market Share Analysis (%) by Expression System, 2022 to 2033
Figure 71: Argentina Market Share Analysis (%) by Application, 2022 to 2033
Figure 72: Argentina Market Share Analysis (%) by End User, 2022 to 2033
Figure 73: Europe Market Value (US$ Million) Analysis, 2017 to 2022
Figure 74: Europe Market Value (US$ Million) Forecast, 2023-2033
Figure 75: Europe Market Value Share, by Virus (2023 E)
Figure 76: Europe Market Value Share, by Expression System (2023 E)
Figure 77: Europe Market Value Share, by Application (2023 E)
Figure 78: Europe Market Value Share, by End User (2023 E)
Figure 79: Europe Market Value Share, by Country (2023 E)
Figure 80: Europe Market Attractiveness Analysis by Virus, 2023 to 2033
Figure 81: Europe Market Attractiveness Analysis by Expression System, 2023 to 2033
Figure 82: Europe Market Attractiveness Analysis by Application, 2023 to 2033
Figure 83: Europe Market Attractiveness Analysis by End User, 2023 to 2033
Figure 84: Europe Market Attractiveness Analysis by Country, 2023 to 2033
Figure 85: UK Market Value Proportion Analysis, 2022
Figure 86: Global Vs. UK Growth Comparison
Figure 87: UK Market Share Analysis (%) by Virus, 2022 to 2033
Figure 88: UK Market Share Analysis (%) by Expression System, 2022 to 2033
Figure 89: UK Market Share Analysis (%) by Application, 2022 to 2033
Figure 90: UK Market Share Analysis (%) by End User, 2022 to 2033
Figure 91: Germany Market Value Proportion Analysis, 2022
Figure 92: Global Vs. Germany Growth Comparison
Figure 93: Germany Market Share Analysis (%) by Virus, 2022 to 2033
Figure 94: Germany Market Share Analysis (%) by Expression System, 2022 to 2033
Figure 95: Germany Market Share Analysis (%) by Application, 2022 to 2033
Figure 96: Germany Market Share Analysis (%) by End User, 2022 to 2033
Figure 97: Italy Market Value Proportion Analysis, 2022
Figure 98: Global Vs. Italy Growth Comparison
Figure 99: Italy Market Share Analysis (%) by Virus, 2022 to 2033
Figure 100: Italy Market Share Analysis (%) by Expression System, 2022 to 2033
Figure 101: Italy Market Share Analysis (%) by Application, 2022 to 2033
Figure 102: Italy Market Share Analysis (%) by End User, 2022 to 2033
Figure 103: France Market Value Proportion Analysis, 2022
Figure 104: Global Vs France Growth Comparison
Figure 105: France Market Share Analysis (%) by Virus, 2022 to 2033
Figure 106: France Market Share Analysis (%) by Expression System, 2022 to 2033
Figure 107: France Market Share Analysis (%) by Application, 2022 to 2033
Figure 108: France Market Share Analysis (%) by End User, 2022 to 2033
Figure 109: Spain Market Value Proportion Analysis, 2022
Figure 110: Global Vs Spain Growth Comparison
Figure 111: Spain Market Share Analysis (%) by Virus, 2022 to 2033
Figure 112: Spain Market Share Analysis (%) by Expression System, 2022 to 2033
Figure 113: Spain Market Share Analysis (%) by Application, 2022 to 2033
Figure 114: Spain Market Share Analysis (%) by End User, 2022 to 2033
Figure 115: Russia Market Value Proportion Analysis, 2022
Figure 116: Global Vs Russia Growth Comparison
Figure 117: Russia Market Share Analysis (%) by Virus, 2022 to 2033
Figure 118: Russia Market Share Analysis (%) by Expression System, 2022 to 2033
Figure 119: Russia Market Share Analysis (%) by Application, 2022 to 2033
Figure 120: Russia Market Share Analysis (%) by End User, 2022 to 2033
Figure 121: BENELUX Market Value Proportion Analysis, 2022
Figure 122: Global Vs BENELUX Growth Comparison
Figure 123: BENELUX Market Share Analysis (%) by Virus, 2022 to 2033
Figure 124: BENELUX Market Share Analysis (%) by Expression System, 2022 to 2033
Figure 125: BENELUX Market Share Analysis (%) by Application, 2022 to 2033
Figure 126: BENELUX Market Share Analysis (%) by End User, 2022 to 2033
Figure 127: East Asia Market Value (US$ Million) Analysis, 2017 to 2022
Figure 128: East Asia Market Value (US$ Million) Forecast, 2023-2033
Figure 129: East Asia Market Value Share, by Virus (2023 E)
Figure 130: East Asia Market Value Share, by Expression System (2023 E)
Figure 131: East Asia Market Value Share, by Application (2023 E)
Figure 132: East Asia Market Value Share, by End User (2023 E)
Figure 133: East Asia Market Value Share, by Country (2023 E)
Figure 134: East Asia Market Attractiveness Analysis by Virus, 2023 to 2033
Figure 135: East Asia Market Attractiveness Analysis by Expression System, 2023 to 2033
Figure 136: East Asia Market Attractiveness Analysis by Application, 2023 to 2033
Figure 137: East Asia Market Attractiveness Analysis by End User, 2023 to 2033
Figure 138: East Asia Market Attractiveness Analysis by Country, 2023 to 2033
Figure 139: China Market Value Proportion Analysis, 2022
Figure 140: Global Vs. China Growth Comparison
Figure 141: China Market Share Analysis (%) by Virus, 2022 to 2033
Figure 142: China Market Share Analysis (%) by Expression System, 2022 to 2033
Figure 143: China Market Share Analysis (%) by Application, 2022 to 2033
Figure 144: China Market Share Analysis (%) by End User, 2022 to 2033
Figure 145: Japan Market Value Proportion Analysis, 2022
Figure 146: Global Vs. Japan Growth Comparison
Figure 147: Japan Market Share Analysis (%) by Virus, 2022 to 2033
Figure 148: Japan Market Share Analysis (%) by Expression System, 2022 to 2033
Figure 149: Japan Market Share Analysis (%) by Application, 2022 to 2033
Figure 150: Japan Market Share Analysis (%) by End User, 2022 to 2033
Figure 151: South Korea Market Value Proportion Analysis, 2022
Figure 152: Global Vs South Korea Growth Comparison
Figure 153: South Korea Market Share Analysis (%) by Virus, 2022 to 2033
Figure 154: South Korea Market Share Analysis (%) by Expression System, 2022 to 2033
Figure 155: South Korea Market Share Analysis (%) by Application, 2022 to 2033
Figure 156: South Korea Market Share Analysis (%) by End User, 2022 to 2033
Figure 157: South Asia Market Value (US$ Million) Analysis, 2017 to 2022
Figure 158: South Asia Market Value (US$ Million) Forecast, 2023-2033
Figure 159: South Asia Market Value Share, by Virus (2023 E)
Figure 160: South Asia Market Value Share, by Expression System (2023 E)
Figure 161: South Asia Market Value Share, by Application (2023 E)
Figure 162: South Asia Market Value Share, by End User (2023 E)
Figure 163: South Asia Market Value Share, by Country (2023 E)
Figure 164: South Asia Market Attractiveness Analysis by Virus, 2023 to 2033
Figure 165: South Asia Market Attractiveness Analysis by Expression System, 2023 to 2033
Figure 166: South Asia Market Attractiveness Analysis by Application, 2023 to 2033
Figure 167: South Asia Market Attractiveness Analysis by End User, 2023 to 2033
Figure 168: South Asia Market Attractiveness Analysis by Country, 2023 to 2033
Figure 169: India Market Value Proportion Analysis, 2022
Figure 170: Global Vs. India Growth Comparison
Figure 171: India Market Share Analysis (%) by Virus, 2022 to 2033
Figure 172: India Market Share Analysis (%) by Expression System, 2022 to 2033
Figure 173: India Market Share Analysis (%) by Application, 2022 to 2033
Figure 174: India Market Share Analysis (%) by End User, 2022 to 2033
Figure 175: Indonesia Market Value Proportion Analysis, 2022
Figure 176: Global Vs. Indonesia Growth Comparison
Figure 177: Indonesia Market Share Analysis (%) by Virus, 2022 to 2033
Figure 178: Indonesia Market Share Analysis (%) by Expression System, 2022 to 2033
Figure 179: Indonesia Market Share Analysis (%) by Application, 2022 to 2033
Figure 180: Indonesia Market Share Analysis (%) by End User, 2022 to 2033
Figure 181: Malaysia Market Value Proportion Analysis, 2022
Figure 182: Global Vs. Malaysia Growth Comparison
Figure 183: Malaysia Market Share Analysis (%) by Virus, 2022 to 2033
Figure 184: Malaysia Market Share Analysis (%) by Expression System, 2022 to 2033
Figure 185: Malaysia Market Share Analysis (%) by Application, 2022 to 2033
Figure 186: Malaysia Market Share Analysis (%) by End User, 2022 to 2033
Figure 187: Thailand Market Value Proportion Analysis, 2022
Figure 188: Global Vs. Thailand Growth Comparison
Figure 189: Thailand Market Share Analysis (%) by Virus, 2022 to 2033
Figure 190: Thailand Market Share Analysis (%) by Expression System, 2022 to 2033
Figure 191: Thailand Market Share Analysis (%) by Application, 2022 to 2033
Figure 192: Thailand Market Share Analysis (%) by End User, 2022 to 2033
Figure 193: Oceania Market Value (US$ Million) Analysis, 2017 to 2022
Figure 194: Oceania Market Value (US$ Million) Forecast, 2023-2033
Figure 195: Oceania Market Value Share, by Virus (2023 E)
Figure 196: Oceania Market Value Share, by Expression System (2023 E)
Figure 197: Oceania Market Value Share, by Application (2023 E)
Figure 198: Oceania Market Value Share, by End User (2023 E)
Figure 199: Oceania Market Value Share, by Country (2023 E)
Figure 200: Oceania Market Attractiveness Analysis by Virus, 2023 to 2033
Figure 201: Oceania Market Attractiveness Analysis by Expression System, 2023 to 2033
Figure 202: Oceania Market Attractiveness Analysis by Application, 2023 to 2033
Figure 203: Oceania Market Attractiveness Analysis by End User, 2023 to 2033
Figure 204: Oceania Market Attractiveness Analysis by Country, 2023 to 2033
Figure 205: Australia Market Value Proportion Analysis, 2022
Figure 206: Global Vs. Australia Growth Comparison
Figure 207: Australia Market Share Analysis (%) by Virus, 2022 to 2033
Figure 208: Australia Market Share Analysis (%) by Expression System, 2022 to 2033
Figure 209: Australia Market Share Analysis (%) by Application, 2022 to 2033
Figure 210: Australia Market Share Analysis (%) by End User, 2022 to 2033
Figure 211: New Zealand Market Value Proportion Analysis, 2022
Figure 212: Global Vs New Zealand Growth Comparison
Figure 213: New Zealand Market Share Analysis (%) by Virus, 2022 to 2033
Figure 214: New Zealand Market Share Analysis (%) by Expression System, 2022 to 2033
Figure 215: New Zealand Market Share Analysis (%) by Application, 2022 to 2033
Figure 216: New Zealand Market Share Analysis (%) by End User, 2022 to 2033
Figure 217: Middle East & Africa Market Value (US$ Million) Analysis, 2017 to 2022
Figure 218: Middle East & Africa Market Value (US$ Million) Forecast, 2023-2033
Figure 219: Middle East & Africa Market Value Share, by Virus (2023 E)
Figure 220: Middle East & Africa Market Value Share, by Expression System (2023 E)
Figure 221: Middle East & Africa Market Value Share, by Application (2023 E)
Figure 222: Middle East & Africa Market Value Share, by End User (2023 E)
Figure 223: Middle East & Africa Market Value Share, by Country (2023 E)
Figure 224: Middle East & Africa Market Attractiveness Analysis by Virus, 2023 to 2033
Figure 225: Middle East & Africa Market Attractiveness Analysis by Expression System, 2023 to 2033
Figure 226: Middle East & Africa Market Attractiveness Analysis by Application, 2023 to 2033
Figure 227: Middle East & Africa Market Attractiveness Analysis by End User, 2023 to 2033
Figure 228: Middle East & Africa Market Attractiveness Analysis by Country, 2023 to 2033
Figure 229: GCC Countries Market Value Proportion Analysis, 2022
Figure 230: Global Vs GCC Countries Growth Comparison
Figure 231: GCC Countries Market Share Analysis (%) by Virus, 2022 to 2033
Figure 232: GCC Countries Market Share Analysis (%) by Expression System, 2022 to 2033
Figure 233: GCC Countries Market Share Analysis (%) by Application, 2022 to 2033
Figure 234: GCC Countries Market Share Analysis (%) by End User, 2022 to 2033
Figure 235: Türkiye Market Value Proportion Analysis, 2022
Figure 236: Global Vs. Türkiye Growth Comparison
Figure 237: Türkiye Market Share Analysis (%) by Virus, 2022 to 2033
Figure 238: Türkiye Market Share Analysis (%) by Expression System, 2022 to 2033
Figure 239: Türkiye Market Share Analysis (%) by Application, 2022 to 2033
Figure 240: Türkiye Market Share Analysis (%) by End User, 2022 to 2033
Figure 241: South Africa Market Value Proportion Analysis, 2022
Figure 242: Global Vs. South Africa Growth Comparison
Figure 243: South Africa Market Share Analysis (%) by Virus, 2022 to 2033
Figure 244: South Africa Market Share Analysis (%) by Expression System, 2022 to 2033
Figure 245: South Africa Market Share Analysis (%) by Application, 2022 to 2033
Figure 246: South Africa Market Share Analysis (%) by End User, 2022 to 2033
Figure 247: North Africa Market Value Proportion Analysis, 2022
Figure 248: Global Vs North Africa Growth Comparison
Figure 249: North Africa Market Share Analysis (%) by Virus, 2022 to 2033
Figure 250: North Africa Market Share Analysis (%) by Expression System, 2022 to 2033
Figure 251: North Africa Market Share Analysis (%) by Application, 2022 to 2033
Figure 252: North Africa Market Share Analysis (%) by End User, 2022 to 2033
